Company Acquires 3,349 Additional BNB Tokens

LineaRx Subsidiary Expected to Narrow Losses and Approach Profitability in FY26Q1

Company Launches New Corporate Website and Branding

BNB Plus Corp. (Nasdaq: BNBX) (“BNBX” or the “Company”), today provided a corporate update highlighting its recent strategic treasury growth, expected significant narrowing of losses at its LineaRx, Inc. (“LineaRx”) subsidiary, and the launch of a new corporate website and branding.

Significant Addition to BNB Treasury

The Company has opportunistically deployed an additional approximately $3 million to acquire additional BNB tokens at an average price of approximately $895 per token, further strengthening the Company’s yield focused BNB treasury strategy. The Company now holds a total of approximately 18,840 BNB through direct holdings and OBNB trust units.

Management continues to view BNB as a foundational strategic asset with meaningful long-term potential that remains broadly underappreciated. Consistent with that view, the Company intends to maintain a disciplined accumulation strategy aligned with its long-term value creation objectives. In parallel, the Company is advancing its efforts to integrate DeFi-based and native Binance yield opportunities directly into its operating and treasury framework, with the goal of generating durable yield, enhancing balance-sheet productivity, and driving sustained shareholder value.

LineaRx Subsidiary Expected to Narrow Losses and Approach Profitability

Following a comprehensive strategic restructuring and realignment of resources implemented earlier this year, LineaRx has significantly reduced its costs while maintaining its industry-leading capabilities in cell-free DNA production. Based on its reduced costs and an increase in customer shipments, the Company expects LineaRx to significantly narrow its losses for FY26Q1 (ending December 31, 2025) and approach profitability. Management views this milestone as a clear validation of its strategic realignment and believes it positions LineaRx to add accretive value beyond the Company’s BNB-based treasury strategy.

Launch of New Corporate Website and Rebranding

The Company recently launched its new corporate website at BNB.plus, together with an updated corporate logo. The refreshed branding and digital presence reflect BNBX’s dual mandate as both an active operator in high-growth biotechnology segments and a leading corporate holder and beneficiary of the BNB token and broader Binance ecosystem. Visitors to BNB.plus will find streamlined access to investor materials, subsidiary updates, treasury statistics, and governance information.

"We believe that executing a successful digital asset treasury strategy requires more than simply accumulating a target asset - it demands operational efficiency across every aspect of a company,” said Clay Shorrock, CEO and President of BNB Plus. “With a right-sized operating company engaged in the rapidly expanding genetic medicine and diagnostic manufacturing markets, a disciplined and strategic accumulation of BNB and the completion of our corporate rebrand, we believe we have established a strong foundation on which to build the next chapter of shareholder value."

About BNB Plus Corp.

BNB Plus unlocks streamlined access to the Binance ecosystem, delivering non-directional yield strategies and long BNB exposure, powering the future of blockchain through a transparent, actively managed BNB treasury. The Company’s differentiated strategy blends sophisticated DeFi yield generation with Binance-native opportunities, unlocking access to high-performance digital assets for investors traditionally excluded from the space. Formally Applied DNA Sciences, Inc., BNB Plus continues to commercialize proprietary nucleic acid production solutions for the biopharmaceutical and diagnostics markets.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “intend,” “objective,” “plan,” “potential,” “could,” “may,” “will,” “believe,” “goal,” “project,” and other words of similar meaning. Forward-looking statements are statements other than historical facts and address various matters including, without limitation, statements relating to the assets held by the Company, the expected future market, price and liquidity of the digital assets the Company holds or acquires, the expecting narrowing of losses and potential profitability for its LineaRx subsidiary, the Company’s plan for value creation and strategic advantages, market size, market position, and growth opportunities, future announcements and priorities, expectations regarding management, future financial and operating condition and performance, and other projections or statements of plans and objectives.

These forward-looking statements are based on current expectations, estimates, assumptions, and projections, and involve known and unknown risks, uncertainties, and other factors—many of which are beyond the Company’s control—that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, failure to realize the anticipated benefits of the proposed digital asset treasury strategy; changes in business, market, financial, political and regulatory conditions, risks relating to the Company’s operations and business, including the highly volatile nature of the price of BNB and other cryptocurrencies, the illiquidity of the OBNB trust units owned by the Company, risks related to the Company’s ability to raise and deploy capital effectively, risks relating to an unproven yield generation strategy, the risk that the price of the Company’s common stock may be highly correlated to the price of the digital assets that it holds, risks related to increased competition in the industries in which the Company does and will operate, the unknown future customer demand for DNA produced by its LineaRx subsidiary, risks relating to significant legal, commercial, regulatory and technical uncertainty regarding digital assets generally, risks relating to the treatment of crypto assets for U.S. and foreign tax purposes, risks related to the unknown returns, liquidity and/or token accumulation that the Company’s BNB treasury strategy will generate, risks relating to market volatility, cybersecurity and custody of digital assets, potential changes in laws or accounting standards relating to cryptocurrency, and regulatory developments affecting BNB or other digital assets, as well as those risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements.

Visit www.BNB.plus for more information. Follow us on X and LinkedIn. Join our mailing list.

Web: www.BNB.plus

X: BNBX_Corp

View source version on businesswire.com: https://www.businesswire.com/news/home/20251209674863/en/